Suppr超能文献

31种美国食品药品监督管理局批准的小分子激酶抑制剂对分离的大鼠肝脏线粒体的影响。

Effects of 31 FDA approved small-molecule kinase inhibitors on isolated rat liver mitochondria.

作者信息

Zhang Jun, Salminen Alec, Yang Xi, Luo Yong, Wu Qiangen, White Matthew, Greenhaw James, Ren Lijun, Bryant Matthew, Salminen William, Papoian Thomas, Mattes William, Shi Qiang

机构信息

Division of Systems Biology, National Center for Toxicological Research, Food and Drug Administration, 3900 NCTR Road, Jefferson, AR, 72079, USA.

Biomedical Engineering 2016, University of Arkansas, Fayetteville, AR, 72701, USA.

出版信息

Arch Toxicol. 2017 Aug;91(8):2921-2938. doi: 10.1007/s00204-016-1918-1. Epub 2016 Dec 28.

Abstract

The FDA has approved 31 small-molecule kinase inhibitors (KIs) for human use as of November 2016, with six having black box warnings for hepatotoxicity (BBW-H) in product labeling. The precise mechanisms and risk factors for KI-induced hepatotoxicity are poorly understood. Here, the 31 KIs were tested in isolated rat liver mitochondria, an in vitro system recently proposed to be a useful tool to predict drug-induced hepatotoxicity in humans. The KIs were incubated with mitochondria or submitochondrial particles at concentrations ranging from therapeutic maximal blood concentrations (Cmax) levels to 100-fold Cmax levels. Ten endpoints were measured, including oxygen consumption rate, inner membrane potential, cytochrome c release, swelling, reactive oxygen species, and individual respiratory chain complex (I-V) activities. Of the 31 KIs examined only three including sorafenib, regorafenib and pazopanib, all of which are hepatotoxic, caused significant mitochondrial toxicity at concentrations equal to the Cmax, indicating that mitochondrial toxicity likely contributes to the pathogenesis of hepatotoxicity associated with these KIs. At concentrations equal to 100-fold Cmax, 18 KIs were found to be toxic to mitochondria, and among six KIs with BBW-H, mitochondrial injury was induced by regorafenib, lapatinib, idelalisib, and pazopanib, but not ponatinib, or sunitinib. Mitochondrial liability at 100-fold Cmax had a positive predictive power (PPV) of 72% and negative predictive power (NPV) of 33% in predicting human KI hepatotoxicity as defined by product labeling, with the sensitivity and specificity being 62% and 44%, respectively. Similar predictive power was obtained using the criterion of Cmax ≥1.1 µM or daily dose ≥100 mg. Mitochondrial liability at 1-2.5-fold Cmax showed a 100% PPV and specificity, though the NPV and sensitivity were 32% and 14%, respectively. These data provide novel mechanistic insights into KI hepatotoxicity and indicate that mitochondrial toxicity at therapeutic levels can help identify hepatotoxic KIs.

摘要

截至2016年11月,美国食品药品监督管理局(FDA)已批准31种小分子激酶抑制剂(KIs)用于人类,其中六种在产品标签中有肝毒性黑框警告(BBW-H)。KI诱导肝毒性的确切机制和危险因素尚不清楚。在此,在分离的大鼠肝线粒体中对这31种KIs进行了测试,最近有人提出体外系统是预测人类药物性肝毒性的有用工具。将KIs与线粒体或亚线粒体颗粒在从治疗性最大血药浓度(Cmax)水平到100倍Cmax水平的浓度下孵育。测量了十个终点指标,包括氧消耗率、内膜电位、细胞色素c释放、肿胀、活性氧以及各个呼吸链复合体(I-V)的活性。在所检测的31种KIs中,只有三种,包括索拉非尼、瑞戈非尼和帕唑帕尼,这三种均具有肝毒性,在等于Cmax的浓度下引起显著的线粒体毒性,表明线粒体毒性可能与这些KIs相关的肝毒性发病机制有关。在等于100倍Cmax的浓度下,发现18种KIs对线粒体有毒性,在六种有BBW-H的KIs中,瑞戈非尼、拉帕替尼、idelalisib和帕唑帕尼可诱导线粒体损伤,但波纳替尼或舒尼替尼则不会。在预测产品标签所定义的人类KI肝毒性方面,100倍Cmax时的线粒体易损性具有72%的阳性预测值(PPV)和33%的阴性预测值(NPV),敏感性和特异性分别为62%和44%。使用Cmax≥1.1µM或每日剂量≥100mg的标准可获得类似的预测能力。1-2.5倍Cmax时的线粒体易损性显示PPV和特异性为100%,尽管NPV和敏感性分别为32%和14%。这些数据为KI肝毒性提供了新的机制见解,并表明治疗水平下的线粒体毒性有助于识别具有肝毒性的KIs。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8fcb/5515969/43da1d95e67c/204_2016_1918_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验